To compare the detection and compliance rates of HBV serum markers between ELISA and ECLIA, and to provide a basis for hospitals to retain or resume the ELISA method. METHODS: ELISA and ECLIA were used to detect HBV serum markers in 139 serum specimens in parallel. RESULTS: Of the 139 specimens, 97 showed complete agreement between the two methods, with a compliance rate of 69.78%. Except for HBeAg (detection rate of ECLIA method was 69.04%, significantly higher than that of ELISA method, P<0.001), the detection rates of other single items were similar without statistical differences (P>0.05). The concordance rate of the results of the individual assays was high, which were all above 80% (83.45%-96.40%). CONCLUSION: The ELISA method still has similar application value as the ECLIA method in conducting HBV seroepidemiologic investigation, observing the immunological response to HBV infection, and screening the health of personnel engaged in special types of work, etc. Hospitals at all levels should continue to retain or resume the ELISA method. HBV infection; serological markers; enzyme-linked immunosorbent assay (ELISA); electrochemiluminescence immunoassay (ECLIA) Serological markers of HBV infection include HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc, which are commonly known as the “five items of hepatitis B”. At present, the most commonly used methods to detect hepatitis B 5 are enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay (ECLIA). Because the specificity and sensitivity of ELISA are not as good as that of ECLIA [1,2], and because of the consideration of economic efficiency, the vast majority of level 3 and some level 2 hospitals have canceled this test method. The aim of this study is to provide a test basis for whether the above hospitals should resume the ELISA method by comparing the detection rate and consistency of the above two methods and the detection of hepatitis B 5 items. I. Subjects: 139 sera were taken from the daily delivery specimens of the outpatient clinic of the Liver Disease Center of the hospital in duplicate and stored at -20 degrees Celsius. Reagents and instruments: ELISA reagents were purchased from Beijing Wantai Bio-pharmaceutical Co., Ltd, and the detection instrument was BIO-RAD MODEL 550; ECLIA reagents were purchased from Yashu Trading (Shanghai) Co., Ltd, and the detection instrument was Abbott architect i2000. Detection method: The preserved serum specimens were rewarmed at room temperature, the same batch of reagents were used, and the test was carried out in strict accordance with the instructions of the reagents, and the test was conducted by two persons in separate rooms, who were unaware of each other’s results before completion of the test. Statistical treatment: χ2 test was used to compare the detection rate (%) of hepatitis B 5 items.